AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Treatment

In a significant development within the pharmaceutical industry, AstraZeneca and its partner Daiichi Sankyo have decided to withdraw their application for the marketing authorization of a lung cancer treatment in the European Union. This decision comes as a blow to both companies, particularly after they had invested substantial resources into the drug's development and regulatory approval.

Continue reading